平衡晶体液与生理盐水在危重症成人中的比较
该实用、整群随机、多次交叉试验在学术中心五个ICU进行,将15802名成人按入住单元随机分配接受生理盐水(0.9%氯化钠)或平衡晶体液(乳酸林格液或Plasma-Lyte A)。主要结局为30天内主要不良肾脏事件复合结局(全因死亡、新发肾脏替代治疗或持续性肾功能不全,定义为肌酐升至基线≥200%),以出院或30天先发生者截尾。平衡晶体液组7942例中1139例(14.3%)发生主要不良肾脏事件,生理盐水组7860例中1211例(15.4%)发生(边际OR 0.91,95%CI 0.84-0.99;条件OR 0.90,95%CI 0.82-0.99;P=0.04)。30天院内死亡率平衡晶体液组10.3% vs 生理盐水组11.1%(P=0.06),新发肾脏替代治疗2.5% vs 2.9%(P=0.08),持续性肾功能不全6.4% vs 6.6%(P=0.60)。
要点
- 在危重症成人中,平衡晶体液组主要不良肾脏事件复合结局发生率为14.3%(1139/7942),生理盐水组为15.4%(1211/7860),边际OR 0.91(95%CI 0.84-0.99),条件OR 0.90(95%CI 0.82-0.99),P=0.04。
- 30天院内死亡率平衡晶体液组10.3% vs 生理盐水组11.1%(P=0.06),差异未达统计学显著。
- 新发肾脏替代治疗发生率平衡晶体液组2.5% vs 生理盐水组2.9%(P=0.08),持续性肾功能不全6.4% vs 6.6%(P=0.60),均未达统计学显著。
- 主要结局定义为30天内全因死亡、新发肾脏替代治疗或持续性肾功能不全(肌酐≥200%基线)的复合结局,以出院或30天先发生者截尾。
- 研究为实用、整群随机、多次交叉试验,在学术中心五个ICU进行,按入住单元随机分配液体类型。
适用人群与场景
- 危重症成人,入住学术中心五个ICU,共15802例,按入住单元随机分配接受生理盐水或平衡晶体液。
诊断标准与关键阈值
- 主要不良肾脏事件复合结局定义为30天内全因死亡、新发肾脏替代治疗或持续性肾功能不全(肌酐升至基线≥200%),以出院或30天先发生者截尾。
处置流程与药物剂量
- 平衡晶体液组接受乳酸林格液或Plasma-Lyte A静脉补液;生理盐水组接受0.9%氯化钠静脉补液。
研究设计与关键结果
- 实用、整群随机、多次交叉试验,在学术中心五个ICU进行,纳入15802名危重症成人,按入住单元随机分配接受生理盐水(0.9%氯化钠)或平衡晶体液(乳酸林格液或Plasma-Lyte A)。
- 主要结局30天内主要不良肾脏事件:平衡晶体液组14.3%(1139/7942) vs 生理盐水组15.4%(1211/7860),边际OR 0.91(95%CI 0.84-0.99),条件OR 0.90(95%CI 0.82-0.99),P=0.04。
- 30天院内死亡率:平衡晶体液组10.3% vs 生理盐水组11.1%(P=0.06)。
- 新发肾脏替代治疗发生率:平衡晶体液组2.5% vs 生理盐水组2.9%(P=0.08)。
- 持续性肾功能不全发生率:平衡晶体液组6.4% vs 生理盐水组6.6%(P=0.60)。
证据类型、等级与局限
- 证据类型:实用、整群随机、多次交叉试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,在危重症成人中,使用平衡晶体液进行静脉补液较生理盐水降低全因死亡、新发肾脏替代治疗或持续性肾功能不全的复合结局发生率。
指南或共识出处
- SMART-MED and SMART-SURG ClinicalTrials.gov numbers, NCT02444988 and NCT02547779。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Both balanced crystalloids and saline are used for intravenous fluid administration in critically ill adults, but it is not known which results in better clinical outcomes.
METHODS: In a pragmatic, cluster-randomized, multiple-crossover trial conducted in five intensive care units at an academic center, we assigned 15,802 adults to receive saline (0.9% sodium chloride) or balanced crystalloids (lactated Ringer's solution or Plasma-Lyte A) according to the randomization of the unit to which they were admitted. The primary outcome was a major adverse kidney event within 30 days - a composite of death from any cause, new renal-replacement therapy, or persistent renal dysfunction (defined as an elevation of the creatinine level to ≥200% of baseline) - all censored at hospital discharge or 30 days, whichever occurred first.
RESULTS: Among the 7942 patients in the balanced-crystalloids group, 1139 (14.3%) had a major adverse kidney event, as compared with 1211 of 7860 patients (15.4%) in the saline group (marginal odds ratio, 0.91; 95% confidence interval [CI], 0.84 to 0.99; conditional odds ratio, 0.90; 95% CI, 0.82 to 0.99; P=0.04). In-hospital mortality at 30 days was 10.3% in the balanced-crystalloids group and 11.1% in the saline group (P=0.06). The incidence of new renal-replacement therapy was 2.5% and 2.9%, respectively (P=0.08), and the incidence of persistent renal dysfunction was 6.4% and 6.6%, respectively (P=0.60).
CONCLUSIONS: Among critically ill adults, the use of balanced crystalloids for intravenous fluid administration resulted in a lower rate of the composite outcome of death from any cause, new renal-replacement therapy, or persistent renal dysfunction than the use of saline. (Funded by the Vanderbilt Institute for Clinical and Translational Research and others; SMART-MED and SMART-SURG ClinicalTrials.gov numbers, NCT02444988 and NCT02547779 .).
参考来源
- Semler MW, Self WH, Wanderer JP, et al. Balanced Crystalloids versus Saline in Critically Ill Adults. N Engl J Med. 2018. PMID: 29485925. doi:10.1056/NEJMoa1711584
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。